Key terms
About MREO
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MREO news
Mar 28
6:30am ET
Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Nuvation Bio (NUVB) and Mereo Biopharma Group Plc (MREO)
Jan 30
1:15pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Jan 30
10:55am ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Jan 15
12:10am ET
Analysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Amarin (AMRN) and Mereo Biopharma Group Plc (MREO)
Jan 08
3:25pm ET
Strategic Partnerships and Regulatory Milestones Bolster Mereo Biopharma’s Growth Prospects
Jan 08
7:59am ET
Mereo BioPharma provides update on pipeline progress, corporate developments
Jan 07
5:41am ET
BTIG Keeps Their Buy Rating on Mereo Biopharma Group Plc (MREO)
Jan 02
9:32am ET
Mereo Biopharma Group Plc (MREO) Gets a Buy from BTIG
Dec 31
5:19am ET
BTIG Keeps Their Buy Rating on Mereo Biopharma Group Plc (MREO)
No recent news articles are available for MREO
No recent press releases are available for MREO
MREO Financials
Key terms
Ad Feedback
MREO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MREO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
